EMT inhibitor-2
EMT inhibitor-2 (Compound 1) inhibits epithelial-mesenchymal transition (EMT) induced by substances such as IL-1β and TGF-β released from the immunocytes. EMT inhibitor-2 inhibits CYP3A4 testosteron and CYP2C9 with IC50s of 49.72 and 5.54 μM, respectively[1].
Product Specifications
CAS Number
[2232228-60-1]
UNSPSC
12352005
Target
Cytochrome P450
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/emt-inhibitor-2.html
Purity
98.83
Solubility
DMSO : 83.33 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
COC1=C(O)C2=C(OC(C3=CC=C(OC)C(OC)=C3)=CC2=O)C=C1OCCN(C4)CCNC4=O
Molecular Formula
C24H26N2O8
Molecular Weight
470.47
References & Citations
[1]Youn, Byung Soo, et al. Substituted chromenes for treatment of fibrosis or non-alcoholic steatohepatitis. US10370364.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
CYP2; CYP3
Available Sizes
Explore Other Products
Browse additional items from our catalog
GBL, CT (MLST8, GBL, LST8, Target of rapamycin complex subunit LST8, G protein beta subunit-like, Mammalian lethal with SEC13 protein 8) (MaxLight 490)
GBL, CT (MLST8, GBL, LST8, Target of rapamycin complex subunit LST8, G protein beta subunit-like, Mammalian lethal with SEC13 protein 8) (MaxLight 490)
